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Epidermal growth factor (EGF) family of receptors is involved in cell growth and diﬀerentiation. The human EGF2 (HER2) lacks
naturalligands,andcorrelationbetweenHER2levelsandcarcinogenesismakesthereceptoranidealcandidatefortargetedtherapy
in breast cancer. Trastuzumab is a humanized antibody applied against HER2-positive breast tumors in clinic. Metastatic tumors
respond well to trastuzumab therapy for the ﬁrst year, but development of antibody resistance helps the tumors to regrow allowing
thediseasetoprogress.Trastuzumabresistanceisshapedviaarangeofintracellularsignalingpathwaysthatareinterconnectedand
share in key eﬀector molecules. Identiﬁcation of a common node central to these resistance pathways could provide an ultimate
solution for trastuzumab resistance in breast and other cancers.
1.Introduction
Breast cancer (BC) originates from the epithelial cells of the
breast tissue that line the terminal duct lobular unit. BC is
the most common cancer type that aﬀects world population.
More than 180,000 new cases of BC were diagnosed in 2008
intheUnitedStatesalone[1].Over40,000ofthesediagnosed
casesresultedindeath,mostlyinwomen[1].BCinwomenis
the most commonly diagnosed cancer that accounts for 26%
of all new cancer cases [2].
Well-known growth signaling pathways contribute to
generation and progression of BC among other cancer
types by promoting cell growth and proliferation [3]. These
signalingpathwaysarepromotedbyanumberofmembrane-
bound and intracellular receptors. The gene expression and
biological activities of these receptors may have great impact
on BC tumor initiation, progression, relapse, and prevention
or treatment. Estrogen receptor (ER), progesterone receptor
(PR), rearranged during transfection (RET), and human
epidermal growth factor 2 (HER2) are the main membrane-
bound receptors playing key roles in BC.
Hormone therapy is directed against ER that is expressed
in 70% of BC tumors. Antibody therapy, on the other hand,
was initiated with development of trastuzumab (TZMB)
that speciﬁcally targets HER2 in 20 to 30% of BC cases
where HER2 is strongly present. Resistance to hormone
therapy and TZMB therapy are two major hurdles in current
clinical BC therapy. In this paper, we will focus on the main
causative sources of TZMB therapy and recent developments
in exploration of key molecules that hold promise for erad-
ication of this resistance.
2. HER2Receptor
The HER/EGF family of receptors consists of four cell-
surface receptors named HER1 (erbB1), HER2 (erbB2),
HER3 (erbB3), and HER4 (erbB4) [4, 5]. These receptors are
involved in cell growth, diﬀerentiation, and survival. They
are activated by a ligand that causes heterodimerization of
these receptors so that a cascade of phosphorylation and sig-
nal transduction events is initiated leading to transcription
of speciﬁc genes involved in cell proliferation and survival
[6]. Receptor dimers that contain HER2 produce stronger
and more prolonged signal transduction event than those
dimmers formed by other HER receptors [4–6].
The gene encoding HER2/neu (erbB2) is a protoonco-
gene located in chromosome 17q21 and encodes a 185-kD
transmembrane glycoprotein with tyrosine kinase activity
[4, 5]. HER2 intracellular domain has a terminal carboxy
segment autophosphorylation of which transmits the extra-
cellular signal into an intracellular signal transduction event.2 International Journal of Breast Cancer
In 20–30% of breast cancer tumors, the HER2 receptor is
either ampliﬁed, overexpressed, or undergoes both events [4,
7]. Receptor overexpression is generally due to gene ampli-
ﬁcation, with one study reporting up to a 25-fold increase in
HER2 copy number [8]. Tumors with HER2 overexpression
generally have a poor disease-free survival [9, 10].
High levels of HER2 have strong correlations with
the pathogenesis, and prognosis of breast cancer [11, 12].
Overexpression of the HER2 protein is detectable both in the
primary tumors and in metastatic sites [13] indicating the
eﬀectiveness of anti-HER2 therapy in all disease locations.
HER2 is distinguished from other HER family members
by lack of a natural ligand which makes the molecule a suit-
able therapeutic candidate. In addition, a strong correlation
exists between HER2 levels and carcinogenesis [14, 15]. High
levels of HER2 found in cancer cell membranes compared to
those of normal cells and HER2 expression in both primary
tumors and metastatic sites have made HER2 inhibitors
important for breast cancer therapy [16, 17].
Research on stem cells as the initiators of breast cancer
development has elucidated the status and function of the
HER2 receptors in BC stem cells (BCSCs). Studies on patient
samples show a signiﬁcant correlation between HER2 over-
expression and the expression of aldehyde dehydrogenase 1
(ALDH1) a key marker for BCSCs [18]. HER2 overexpres-
sion also acts as a driving force for breast stem cell malig-
nancy,mammarytumorigenesisandinvasion[19].Epithelial
cells isolated from normal breast form mammospheres
that are nonadherent and spherical morphologies [20].
HER2 overexpression increases mammosphere formation by
BCSCs [19]. Generation of mammospheres is an indication
of increased self-renewal in these stem cells, whereas the size
of these colonies that indicates proliferation of progenitors is
also increased by HER2. The report by Korkaya and cowork-
ers indicates that HER2 not only increases stem-cell number
but also upregulates the expression of stem cell-related genes
including Oct3/4, Nothc1, Notch2, Jag1, Gli1 in Aldeﬂuor+
cells. HER2 also activates the Akt growth pathway in these
stem cells [19].
3.HER2-ERCrosstalks
Crosstalks between BC cell receptors are important for full
implementation of their biological activities. HER2 interacts
with ER in a variety of approaches. Estradiol as an ER ligand
induces a signal transduction cascade that trans-activates
HER2 via SRC tyrosine kinase and the matrix metallopro-
teases MMP-2 and MMP-9 [21]. ER/HER2 interactions acti-
vate ERK and MAPK pathways and the two receptors equally
contribute to ERK ampliﬁcation in human mammary epi-
thelial cells [22]. Therefore, ER and HER2 act in synergy
to promote aberrant breast tumor growth. Co-expression
of HER2 and ER co-activator A1B1 at high levels enhances
tamoxifenresistance.Infact,inMCF7tumorcelllineoverex-
pressingHER2andA1B1,tamoxifenpromotedtumorigenic-
ity by inducing tumor cell growth both in vitro and in vivo
[23].
4. HER2Inhibitionby Trastuzumab
HER2 was one of the ﬁrst receptors targeted with the
invention of its speciﬁc monoclonal antibody TZMB [24].
The encouraging preclinical results of this therapy took
TZMB to clinic [25]. Currently, TZMB is used alone or as
adjuvant with chemotherapy for treatment of breast cancer,
especially in advanced stages of the disease.
TZMB is a recombinant humanized monoclonal anti-
body directed against the extracellular domain of HER2
inhibiting receptor dimerization [24, 26]. The mechanism
of TZMB action on HER2-overexpressing tumors is not
fully known, but experimental data exist that indicate the
antibody inﬂuences several intracellular pathways all in favor
of tumor cell death [27]. The multiple eﬀects of TZMB can
be explained by HER2 involvement in multiple signaling
pathways. HER2 induces PI3K and MAPK and so activates
downstream growth/proliferation pathways. TZMB-HER2
interaction inhibits these cascades leading to increased levels
of p27Kip ultimately arresting cell cycle and inducing apop-
tosis [28]. Induction of antibody-dependent cellular cyto-
toxicity (ADCC) leading to cancer cell lysis [24, 29]a n d
inhibition of angiogenesis are two other eﬀects of TZMB
in favor of BC treatment. The overall response rate to
TZMB monotherapies is ∼26% compared to 40–60% when
a TZMB-chemotherapy combination is applied [25, 30, 31].
An important function of TZMB on HER2 is to prevent
receptor degradation and cleavage. This function can be
shown by examining serum samples in TZMB-treated pa-
tients who have reduced levels of HER2 shedding in their
serum [32]. TZMB-mediated reduction of HER2 levels in
patients’ serum has been accompanied with improved pro-
gression-free survival and so considered an indicative of host
response to the antibody therapy [33].
In addition to its eﬀect on HER2 dimerization and
cleavage, TZMB can cause HER2 internalization and degra-
dation as shown in HER2-amplifying BC cell lines and
tumor samples treated with the antibody [34, 35]. It is not
clear, however, if TZMB actually contributes to HER2 gene
downregulation, since some studies report unchanged levels
of HER2 upon TZMB treatment [29, 36].
5. Mechanismsof TrastuzumabResistance
Resistance to TZMB therapy occurs in both de novo (intrin-
sic) and acquired forms. The de novo resistance results from
geneticchangesinreceptortyrosinekinases(RTKs)andtheir
downstream cellular pathways. The main genetic changes in
this case include deﬁcient PTEN [37]o rm u t a t e dPIK3CA
genes [38] that cause the constitutive activation of the PI3K
pathway, and expression of a truncated, rather than full
length, HER2 receptors named p95HER2 that lack extracel-
lular domain needed for TZMB binding [39].
The acquired form of TZMB resistance is caused mainly
by shaping compensatory kinase signaling pathways alterna-
tive to HER2-mediated pathways leading to BC cell growth
and TZMB insensitivity. There are also genetic alterations
that are source of both de novo and acquired forms of
resistance. Below, we outline some of the main mechanismsInternational Journal of Breast Cancer 3
behind TZMB resistance that we have summarized in
Table 1.
5.1. Truncated HER2 Versions. In addition to genetically
shortened HER2 receptors, cleavage by metalloproteases
generatesatruncatedHER2receptorlackingtheextracellular
domain required for TZMB binding [57]. The truncated re-
ceptor will retain its kinase activity undisturbed in the ab-
sence of any blocker [39]. The truncated HER2 versions
might be a source of de novo TZMB resistance because
HER2 cleavage can be blocked by TZMB [32] that prevents
resistance to be acquired in the course of treatment.
5.2. HER2 Masking. TZMB can be deprived of reaching and
eﬀectively binding HER2 due to function of the membrane-
bound glycoprotein mucin-4 (MUC4). MUC4 contributes
to BC progression by protecting cancer cells from immune
recognition, inducing tumorigenicity and metastasis, sup-
pressing apoptosis, and activating HER2 [43]. Using its
ASGP-2 subunit that contains an EGF-like domain, MUC4
can directly bind HER2 and induce HER2 phosphorylation.
Through this interaction, MUC4 competes with TZMB for
HER2 binding as shown in BC cell lines overexpressing
MUC4 [44]. Studies on patient-derived cell lines with HER2
ampliﬁcation and de novo resistance to TZMB demonstrated
an inverse correlation between HER2-binding capacities of
MUC4 and TZMB [45]. These observations suggested that
HER2 epitopes are masked by MUC4 which causes steric
hindrance of trastuzumab-HER2 interaction and shapes
antibody resistance.
5.3. Signaling by Other HER Family Members. The four
members of EGFR type 1 growth factor RTK family, namely,
EGFR, HER2, HER3, and HER4 tend to dimerize with
HER2 as a partner of their choice when induced by their
relevant ligands [46]. This heterodimerization results in RTK
activity that is echoed by activation of downstream signal-
ing, components via the MAPK and PI3K pathways. The
function of TZMB is to prevent HER2-mediated signaling
b u ti tc a n n o te ﬀectively inhibit signaling promoted by other
HER receptors. Therefore, heterodimers or homodimers
constituted by EGFR and HER3 may induce PI3K/MAPK
pathways. Growth inhibition induced by TZMB can also be
prevented by the activity of endogenous HER family ligands
thatinduceHER2/HER3andHER2/EGFRsignaling[47,48].
TheseobservationsindicatethattheoveralleﬃcacyofTZMB
can be dictated by the endogenous status of EGFR family
members, their ligands, and inhibitors. Determination of
the levels of these molecules within BC cells could help
to improve TZMB function. Another solution is to block
crosstalks between RTKs using bispeciﬁc antibodies or com-
bination of TZMB and lapatinib or TZMB and pertuzumab
that seem to confer more improvement to recipient patients
[49, 50].
5.4. IGF-1R Signaling. The insulin-like growth factor-1
receptor(IGF-1R)isatransmembranetyrosinekinaserecep-
tor predominantly expressed in human BCs and involved
in proliferation and metastatic dissemination [58]. IGF-1R
interacts with HER2 and contributes to TZMB resistance in
BC cells [59]. Since both IGF-1R and HER2 promote com-
mon downstream pathways of cell growth and proliferation,
the study shows that their cooverexpression inhibits TZMB-
mediated growth inhibition [60]. Therefore, it is likely
that tumors coexpressing the two receptors resist TZMB-
mediated therapy. On the other hand, drugs acting as IGF-
1R antagonists such as IGFBP3 that blocks IGF resensitize
resistant BC cells to the antibody [61]. Like other receptor
kinases, IGF-1R is also dependent on PI3K/Akt pathway for
its biological functions including p27Kip1 degradation [28].
IGF-1R has been further found to induce phosphorylation
of HER2, an activity of IGF-1R observed only in TZMB-
resistant cells [62]. Restoration of TZMB sensitivity in BC
cells upon inhibition of IGF-1R signaling either by antibody-
mediated blockage or IGF-1R tyrosine kinase inhibition
introduces signaling pathways downstream of IGF-1R as
therapeutic targets to break antibody resistance.
5.5. PTEN. Mutated or downregulated PTEN leads to its
loss of function, a phenomenon described in nearly 50%
of breast cancers [63]. Since PTEN has inhibitory eﬀects
on PI3K, loss of PTEN function constitutively maintains
the activity of the PI3K/Akt pathway [37] that inhibits cell-
cycle arrest and apoptosis mediated by TZMB [40]. Patients
with BC tumors that lack PTEN expression but overexpress
HER2 more poorly respond to TZMB therapy than those
patients with normal PTEN expressed by their tumor cells
[37]. Therefore, PTEN loss could provide another indication
for TZMB resistance. In fact, in those patients with tumors
reluctant to respond to TZMB therapy but with high-level
PITEN expression, inhibition of PI3K/Akt pathway could
provide another therapeutic opportunity in clinic, as shown
by TZMB and lapatinib response upon PTEN loss and PI3K
activation [64].
5.6. p27. The cyclin-dependent kinase-inhibiting protein
p27Kip1 mediates growth inhibitory eﬀects of trastuzumab
[42]. Trastuzumab has positive eﬀects on p27Kip1 half-life
[65] and supports formation of p27Kip1-cyclin-dependent
kinase 2 (CDK2) complexes that arrest cell cycle at G1 [66].
In fact, inhibition of p27Kip1 expression blocks trastuzumab-
mediated growth arrest in HER2-overexpressing BC cells
[40]. Overexpression of p27Kip1 or its induction by the pro-
teasome inhibitor MG132 restored trastuzumab sensitivity
that highlights the critical role of p27Kip1 in trastuzumab
function [28]. On the other hand, CDK2 inhibitors result in
reduced cell proliferation and enhanced apoptosis in vitro
and reduced tumor growth in xenografts resistant to trastuz-
umab [67].
5.7. PI3K/Akt Pathways. Earlier we outlined the importance
of PTEN loss in constitutive activation of the PI3K/Akt
pathway leading to TZMB resistance. The pathway can also
be activated via PI3K mutations. PIK3CA that encodes the
catalytic subunit of PI3K is a gene frequently mutated in
breast cancer and promotes TZMB insensitivity in BC cells
in vitro [41]. In vivo studies also point to the anti-TZMB
role played by mutated versions of PIK3CA when applied4 International Journal of Breast Cancer
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with reduced PTEN expression [38]. In parallel, HER2-
ampliﬁed breast cancer cell lines containing PIK3CA hotspot
mutations more signiﬁcantly resisted TZMB than mutant-
free cells [68]. Therefore, the PI3K/Akt pathway provides an-
other landmark for TZMB eﬃcacy.
5.8. Cyclin E Ampliﬁcation/Overexpression. The overexpres-
sion of the cyclin E in BC cell lines and tumor samples has
been proposed as a marker of poor clinical outcome [69].
There are conﬂicting reports on relationships between cyclin
E and HER2. A previous study indicated reduction of cyclin
E levels upon HER2 downregulation and HER2 inhibition
and so suggested cyclin E regulation by HER2 [70]. It is now
emerging from a recent report that cyclin E might have an
impact on HER2 function in BC cells [67]. In this paper,
genome-wide analysis of TZMB-resistant BC cell lines and
tumor cells indicates that cyclin E is ampliﬁed and so over-
expressed in these cell samples. In this study, the ampliﬁed
cycline E gene was found to worsen clinical outcome and
reduce progression-free survival. While cycline E overexpres-
sion enhanced TZMB resistance both in vitro and in vivo,
suppression of cyclin E activity highly reduced cell prolif-
eration and induced apoptosis among cyclin E-amplifying
BC cells. Cyclin E suppression mediated by CDK2 inhibition
reduced tumor growth among xenografts that were insensi-
tive to TZMB [67]. The use of CDK inhibitors could be a
novelapproachtocounteractantibodyresistanceintargeting
HER2.
5.9.AlternativeSignalingPathways. HER2crosstalkswithER
and with RTKs, as we discussed in Section 4, are critical for
activationofsignalingpathwaysleadingtoBCtumorgrowth.
RettyrosinekinaseinteractswithSRCkinaseuponactivating
protein kinase C (PKC) and induces upregulation of many
growth pathways through the function of SRC as key inducer
of TZMB resistance discussed below. More importantly, SRC
mediates Ret/Her2 crosstalks: phosphorylated in its SH2
domain via GDNF/Ret downstream PLC/PKC pathway, SRC
induces Her2 phosphorylation by matrix metalloproeinases
MMP2 and MMP9 (Figure 1)[ 51].
Ret is also in crosstalk with ER for ER gene overexpres-
sion [54] and receptor stabilization [55]. In BC cell lines
resistant to tamoxifen treatment, HER2 signaling pathways
are selected against Ret/ER pathways to promote cell growth
whereas targeting Ret restores drug sensitivity [56]. Phos-
phorylated SRC activates alternative receptors RTKs MET
and FAK both of which promote mitogenesis and cancer
cell growth (Figure 1)[ 52, 53]. MET downstream pathway
includesRAS,RAF,andMAPK/ErK1/2,whereasFAkinduces
Crk/CAS and deregulation of both pathways can promote
cancer cell growth alternative to other receptors.
The capacity of BC cells in switching from one receptor
to another for growth promotion suggests that Ret, like other
RTKs, can induce alternative growth signaling in support
of resistance to TZMB therapy. Although the function of
Ret in TZMB-resistant cells and tumor samples has not
been reported, Ret inhibition might be a novel strategy to
overcome such resistance.
5.10. Immune Response Induction. TZMB-mediated growth
arrest and BC cell death are partially due to the induction
of immune responses by the antibody. Antibody-dependent
cellular cytotoxicity (ADCC) is induced by TZMB and other
antibodies targeting HER2 leading to apoptosis in several BC
cell lines [29, 45, 71].
Anti-HER2 antibody-mediated BC cell death occurs via
natural killer (NK) cells that, by expressing the Fc gamma
receptor, interact with the Fc domain of the antibody [72].
The importance of this interaction has been shown in a
xenograft model of mice lacking Fc receptor where TZMB
could only partially inhibit tumor growth [72]. These ﬁnd-
ings indicated the role of the immune system in sustaining
anti-HER2 therapies.
5.11. SRC: A Proposed Central Node. Based on reports that
SRC is commonly activated in EGFR/IGF-1R-overexpressing
and PTEN-deﬁcient cells, the molecule appears to play a
central role in development of resistance against HER2-
mediated antibody therapy. This is particularly important in
terms of SRC involvement in common events downstream
of key growth signaling pathways and so SRC function as a
common node in promoting TZMB resistance.
SRC encodes a nonreceptor tyrosine kinase that in its
active form contributes to many hallmarks of cancer includ-
ing cell proliferation, migration, and angiogenesis [73, 74].
The SRC family contains four SRC homology domains called
SH and a C-terminal segment that has a negative regulatory
tyrosine residue (Tyr530) [73]. SRC is activated upon phos-
phorylation that is catalyzed by protein tyrosine phosphatase
alpha and SH-containing phosphatases SHP1/SHP2 [73].
On the other hand, SRC kinases including RTKs EGFR,
HER2, FGFR, PDGFR, and VEGFR activate the protein by
phosphorylating it [75].
S R Ci sh y p e r a c t i v a t e di nT Z M BB Cc e l lm o d e l sa n d
has implications for TZMB resistance. For instance, tumor
necrosis factor α (TNFα) induces HER2 phosphorylation in
breast cancer cells via c-Src activation [76]. Another example
is erythropoietin receptor (EpoR) that induces MAPK/Erk
andPI3K/Aktpathways[77].BCcelllinescoexpressingEpoR
and HER2 induce TZMB resistance upon treatment with
recombinant erythropoietin that interacts with phosphory-
lated EpoR [78]. Activated SRC and inactivated PTEN were
found to be behind increased TZMB resistance [78].
SRC activation occurs mainly due to phosphorylation of
Tyr419 and Tyr416 residues [75]. For example, overexpres-
sion of RTKs EGFR and IGF-IR induces Tyr416 phospho-
rylation and promotes antibody resistance whereas siRNA-
mediated suppression of these kinases reduces resistance
[79]. SRC has been shown to inhibit PTEN activity by
inducing tyrosine phosphorylation and blocking PTEN
membrane localization [37, 80] suggesting that SRC and
PTEN may regulate each other to promote TZMB resistance.
Based on these reports, Zhang et al. further examined the
role of SRC in de novo insensitivity of BC tumor cells to
trastuzumab treatment by inhibiting PTEN.
Antisense-orshRNA-mediateddownregulationofPTEN
induced SRC Tyr416 phosphorylation, SRC activation, and6 International Journal of Breast Cancer
MMP2
MMP9
MEK
RAF
RAS
mTOR
Akt
PLC
Promoter
4
2
2
3
P P
PP
1
RET
PP
GDNF
1
3
ER
4 3
P P P P
4 3
MET
P P
3 4
PKC
BCCM
FAK
PI3K
A1B1
HER2
ER
ligand
FAK
ligand
HER2
ligand
MET
ligand
SRC
SRC
CrK/CAS
MAPK
ERK1/2
Cellsurvival/growth/
proliferation genes
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ultimately elevated TZMB resistance, whereas induction of
PTEN phosphatase activity directly dephosphorylated SRC
Tyr416 residue and so abolished SRC activity [79]. These
observations indicate that the loss of PTEN phosphatase
activity induces SRC activation and so implicates SRC in
shaping de novo TZMB resistance in PTEN-deﬁcient cells
[81]. Indeed, hyperphosphorylation of Tyr416 that increases
SRC activity is an inducing factor for TZMB resistance,
whereas Tyr416 dephosphorylation sensitizes BC cells to
TZMB-mediated growth arrest.
The activity of SRC per se and its role in antibody
resistance was examined using both SRC small-molecule
inhibitor saracatinib and SRC shRNA molecules. Inhibi-
tion of SRC halted EGF-induced EGFR dimerization and
inhibited phosphorylation of an EGFR residue known to
be SRC-dependent phosphorylation site [81] and an au-
tophosphorylation site within EGFR [79]. EGFR phospho-
rylation was also inhibited in TZMB-resistant cells treated
with saracatinib. Moreover, treatment with TZMB further
activated SRC due to the transient induction of HER2
dimerization/phosphorylation by TZMB in resistant cells. In
contrast, inactivation of SRC by saracatinib or SRC shRNAs
diminished TZMB-induced transient phosphorylation of
HER2 as well as HER3 [79]. These observations indicate that
SRC hyperactivity in TZMB-resistant BC cells promotes a
positive feedback cycle where SRC activates EGFR, HER2,
and HER3 which, in turn, can activate SRC. Overall, the
report by Zhang et al. highlights the increasing central role
of SRC as common converging point for all the intracellular
forces that contribute to shaping and re-gaining BC cell
resistance toward HER2-directed treatments specially TZMB
therapy.
6. Conclusions andFutureTherapies
TZMB is an antibody of choice for HER2-directed BC
therapies. In patients with metastatic, HER2-positive breast
cancer, TZMB administered as an adjuvant combined with
chemotherapy shows signiﬁcant clinical beneﬁts [25, 80].
However, the majority of HER2-positive patients do not
respond to TZMB due to de novo or acquired resistance. This
review outlined main molecules and major pathways that
causatively contribute to TZMB resistance. Abnormalities
in HER2 structure/function and in downstream signaling
pathways as well as RTK crosstalks have been suspected
causes as evidenced by examination of BC cells and tumor
samplesinvitroandinvivo.Themostrecentstudiespinpoint
to SRC acting as a downstream signaling eﬀector and a
central common node in mediating TZMB resistance.
Receptor crosstalks blocked by bispeciﬁc antibodies or by
TZMB combined with lapatinib or pertuzumab have shown
better clinical outcomes compared to single antibody treat-
ment. Therefore, a multipronged strategy capable of eﬀec-
tively blocking the HER2 signaling network is needed
to inhibit HER2 homodimerization and HER2-RTK het-
erodimerization, so HER2-dependent malignant BC tumors
become fully controllable. Compensation for loss of expres-
sion or activity of several molecules involved in TZMB resis-
tance may partially reverse resistance and resensitize BC cells
and tumors to the antibody. However, disarming common
nodes, for example, by inhibition of SRC expression and or
function holds promise for universally combating resistance
and controlling HER2-positive BC tumors. Coinhibition of
SRC and RTKs that promote bypassing growth pathways
such as Ret, FAK, and Met could provide a global coverage
against TZMB resistance.International Journal of Breast Cancer 7
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